EUVIMEDEUVIMED entdecken
Crossref

Inhibition of Melanoma Growth by Ex Vivo Expanded Tumor‐Specific CD8+ T Cells Is Dependent on the Configuration of Nanoscale Artificial APCs

Antara Mondal, Faisal Jamal, Arpita Das, Arnab Kumar Sahoo, Khushboo Chaudhary, Sarmili Chowdhury, Aakriti Jha, Santiswarup Singha

European Journal of Immunology · 2025

DOI: 10.1002/eji.202451676 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Immunology, 2025. Verfasst von Antara Mondal und 7 weiteren Autor:innen. Beteiligte Einrichtung: Nano-Biotechnology Laboratory, National Institute of Immunology, New Delhi, India. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Immunotherapy, Adoptive, Antigen-Presenting Cells, Melanoma, Experimental. Die Arbeit nennt 41 Literaturangaben. Gefördert von: Department of Biotechnology, Government of India, Ramalingaswami Re-entry Fellowship, Department of Biotechnology, Government of India, Science & Engineering Research Board (SERB), Government of India.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adoptive T‐cell therapy is an emerging immunotherapeutic strategy for treating cancer, but the compromised quality of CD8+ T‐cells limits the therapeutic efficacy. Traditional methods involving polyclonal expansion of CD8+ T‐cells mainly prioritize yielding a high quantity of CD8+ T‐cells. However, the antigen‐specificity of ex vivo expanded CD8+ T‐cells and the ability to produce cytolytic molecules are the two critical determinants of therapeutic efficacy that remain poorly studied. To address this problem, we formulated nanoscale artificial antigen‐presenting cells (a‐APCs) displaying tumor‐specific class‐I peptide‐major histocompatibility complexes (p‐MHC‐I) and co‐stimulatory molecules to expand the antigen‐specific CD8+ T‐cells ex vivo. We found that the magnitude of ex vivo expanded T‐cells was directly proportional to the valency of p‐MHC coated on the a‐APCs. Promisingly, a‐APC with higher valency of p‐MHC yielded CD8+ T‐cells capable of producing a greater extent of cytolytic molecules such as granzyme B and perforin, exhibited excellent therapeutic efficacy by inhibiting the growth of aggressive murine melanoma than the CD8+ T‐cells expanded by lower valency a‐APCs. Our findings emphasize that the valency of p‐MHC is a critical parameter for configuring nanoscale a‐APCs, which governs ex vivo manufacturing of therapeutically potent antigen‐specific CD8+ T‐cells capable of inhibiting the growth of solid tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD8-Positive T-LymphocytesImmunotherapy, AdoptiveAntigen-Presenting CellsMelanoma, ExperimentalMelanomaAnimalsMiceMice, Inbred C57BLGranzymesHistocompatibility Antigens Class IPerforinCell Line, TumorAntigens, NeoplasmArtificial Cells

Stichwörter der Autor:innen

antigen‐specific CD8+ T‐cellsartificial antigen‐presenting cellsex vivo expansionnanoparticlepeptide‐major histocompatibility complexsolid tumorstherapeutic efficacyvalency of p‐MHC

Substanzen

GranzymesHistocompatibility Antigens Class IPerforinAntigens, Neoplasm

Autor:innen und Institutionen

  • Nano-Biotechnology Laboratory, National Institute of Immunology, New Delhi, India.

Förderung

  • Department of Biotechnology, Government of India
  • Ramalingaswami Re-entry Fellowship, Department of Biotechnology, Government of India
  • Science & Engineering Research Board (SERB), Government of India
  • Indian Council of Medical Research, Government of India
  • National Institute of Immunology.

Zitieren

APA

Mondal, A., Jamal, F., Das, A., Sahoo, A. K., Chaudhary, K., Chowdhury, S., Jha, A., & Singha, S. (2025). Inhibition of Melanoma Growth by Ex Vivo Expanded Tumor‐Specific CD8+ T Cells Is Dependent on the Configuration of Nanoscale Artificial APCs. European Journal of Immunology. https://doi.org/10.1002/eji.202451676

Vancouver

Mondal A, Jamal F, Das A, Sahoo AK, Chaudhary K, Chowdhury S, et al. Inhibition of Melanoma Growth by Ex Vivo Expanded Tumor‐Specific CD8+ T Cells Is Dependent on the Configuration of Nanoscale Artificial APCs. European Journal of Immunology. 2025. doi:10.1002/eji.202451676

BibTeX
@article{Mondal2025,
  author = {Mondal, Antara and Jamal, Faisal and Das, Arpita and Sahoo, Arnab Kumar and Chaudhary, Khushboo and Chowdhury, Sarmili and Jha, Aakriti and Singha, Santiswarup},
  title = {Inhibition of Melanoma Growth by Ex Vivo Expanded Tumor‐Specific CD8+ T Cells Is Dependent on the Configuration of Nanoscale Artificial APCs},
  journal = {European Journal of Immunology},
  year = {2025},
  doi = {10.1002/eji.202451676}
}
Kostenlos starten →